Medicure Inc. is a Canada-based pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. The Company’s primary, non-AGGRASTAT research and development activity is TARDOXAL for the treatment of Tardive Dyskinesia (TD). AGGRASTAT, a glycoprotein GP IIb or IIIa receptor antagonist, is used for the treatment of acute coronary syndrome (ACS), including unstable angina, which is characterized by chest pain when one is at rest, and non-Q-wave myocardial infarction. American Cardio Therapeutics Inc., a Company that is 49% owned by Medicure Pharma Inc.